CoChat

Variation in Inflammatory Markers and Glycemic Parameters After 12 Months of Exenatide Plus Metformin Treatment Compared with Metformin Alone: A Randomized Placebo‐Controlled Trial

Derosa, Giuseppe, Franzetti, Ivano G., Querci, Fabrizio, Carbone, Anna, Ciccarelli, Leonardina, Piccinni, Mario N., Fogari, Elena, Maffioli, Pamela · 2013 · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Cited by 29

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Study Objective: To evaluate the effects of exenatide on some inflammatory markers and to quantify the effect of exenatide on β‐cell function. Design: A randomized, double‐blind, placebo‐controlled trial. Setting: Seven hospitals in I taly. Patients: A total of 174 white treatment‐naive adults with type 2 diabetes and a glycated hemoglobin (HbA 1c ) level higher than 7.5%. Intervention: After an open‐label run‐in period of 8 ± 2 months with metformin, patients were randomized to take exenatide (5 μg twice/day for the first 4 weeks, 10 μg twice/day thereafter) or a placebo volume equivalent for 12 months. Measurements and Main Results: Body mass index, H b A 1c , fasting plasma glucose, postprandial plasma glucose, fasting plasma insulin ( FPI ), homeostasis model assessment insulin resistance index, homeostasis model assessment β‐cell function index ( HOMA ‐β), fasting plasma proinsulin ( FPP r), proinsulin‐to‐fasting plasma insulin ratio (Pr: FPI ratio), C ‐peptide, glucagon, vaspin, chemerin, and resistin were evaluated at baseline, at randomization, and at 3, 6, 9, and 12 months. Patients also underwent a combined euglycemic, hyperinsulinemic, and hyperglycemic clamp with subsequent arginine stimulation to assess insulin sensitivity and insulin secretion. H b A 1c was significantly improved with exenatide plus metformin compared with placebo plus metformin. Exenatide plus metformin was also significantly more effective than placebo plus metformin in increasing HOMA ‐β C‐peptide, and all measures of β‐cell function after the euglycemic hyperinsulinemic and hyperglycemic clamp. We observed that exenatide plus metformin also reduced resistin compared with placebo plus metformin. No variations in vaspin and chemerin were noted in group‐to‐group comparisons. We observed a significant correlation between M value increase, an index of insulin sensitivity, and a decrease in inflammatory parameters in the exenatide plus metformin group. Conclusions: The combination of exenatide plus metformin was more effective than metformin alone in improving glycemic control, β‐cell function, and inflammatory parameters.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/phar.1301

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

Metadata

Authors
Derosa, G., Franzetti, I. G., Querci, F., Carbone, A., Ciccarelli, L., Piccinni, M. N., Fogari, E., & Maffioli, P.
Venue
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Publisher
Wiley
Published
2013-06-06
Volume
33
Issue
8
Pages
817-826
ISSN
  • 0277-0008 (ISSN-L)
  • 1875-9114
OpenAlex
W2036806748
Cited by
29
References
7
FWCI
2.36
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.